Merck Animal Health Announces Availability of INNOVAX®-ILT-IBD Vaccine

Novel vaccine provides protection in poultry flocks against the challenges from MD, ILT and IBD in a single injection

RAHWAY, N.J., Feb. 2, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that INNOVAX^®-ILT-IBD vaccine is commercially available as part of its poultry product portfolio. The company received license approval for the vaccine in the U.S. from the Department of Agriculture (USDA) in 2024.

INNOVAX-ILT-IBD provides combined protection and immunization against Marek’s disease (MD), infectious laryngotracheitis (ILT) and infectious bursal disease (IBD) in a single injection. It can be administered in the hatchery to layers and breeder flocks to increase early-life protection, and to broilers, both by subcutaneous injection at day-old or in ovo application at 18 days of incubation.

Building on Merck Animal Health’s legacy of protection offered by INNOVAX-ILT, INNOVAX-ILT-IBD features two glycoprotein inserts instead of one and provides twice the protection against ILT, in addition to the IBD antigen. This unique combination of two glycoproteins (gD and gl) ensures a robust cellular immune response and a neutralizing antibody response.

“Merck Animal Health continues to shape the future of animal health by continuing to develop innovative, science-driven ways to preserve poultry health and performance while maximizing our customers’ productivity,” said Charles Broussard, D.V.M., senior account manager for poultry sales, Merck Animal Health. “In commercial poultry farming, viral infections can lead to significant economic losses if flocks are not sufficiently protected through vaccinations as pathogens can spread rapidly among birds. INNOVAX-ILT-IBD provides protection against three of the most common viruses that affect poultry flocks.”

Vaccination with INNOVAX-ILT-IBD in the hatchery provides scientifically demonstrated protection as early as five days for MD, 14 days for IBD and 28 days for ILT.

INNOVAX-ILT-IBD is available in a 2,000-dose ampoule. For more information about INNOVAX-ILT-IBD, contact your Merck Animal Health sales or technical services representative or visit https://www.merck-animal-health-usa.com/innovax/innovax-ilt-ibd.

INNOVAX-ILT-IBD PRODUCT LABEL

Merck Animal Health introduces INNOVAX-ILT-IBD, which provides combined protection against Marek’s disease (MD), infectious laryngotracheitis (ILT) and infectious bursal disease (IBD) in a single injection providing immunization against all three viruses.

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals^®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

---